Measurable Residual Disease in ALL: Proof of the Principle Transforming Care for Patients With Hematologic Malignancies
  • CME
  • CE

This expert panel examines the importance of incorporating MRD testing in ALL and the use of blinatumomab in MRD-positive ALL after CR to provide your patients with better outcomes
Elias Jabbour, MD
Program Director
Joseph D. Khoury, MD
person default
Aaron C. Logan, MD, PhD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.2 Nursing contact hours
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: November 1, 2018 Expiration: October 31, 2019
Multimedia Measurable Residual Disease in ALL: Proof of the Principle Transforming Care for Patients With Hematologic Malignancies
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
Measurable Residual Disease in ALL
Aaron C. Logan, MD, PhD, explains why testing for measurable residual disease is essential for patients with ALL.
Launch Measurable Residual Disease in ALL
Methods for Quantifying MRD
Joseph D. Khoury, MD, discusses the benefits and limitations of assays used for MRD testing in ALL.
Launch Methods for Quantifying MRD
Treatment Options for MRD-Positive ALL
Elias Jabbour, MD, details the use of blinatumomab in MRD-positive patients with ALL to achieve better outcomes.
Launch Treatment Options for MRD-Positive ALL

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss when to test for MRD in patients with ALL
  • Describe the different tests for MRD and how to obtain them
  • Work with pathologists to determine MRD positivity, based on the test used, in patients with ALL
  • Select appropriate treatment options for patients with MRD-positive ALL
  • Answer patient questions regarding the use of MRD to diagnose disease that is present after induction that requires additional treatment in ALL and soon in other diseases

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

In partnership with
Grace Logo
This activity is supported by educational grants from
Adaptive Biotechnologies
Amgen

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Elias Jabbour, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elias Jabbour, MD, has no real or apparent conflicts of interest to report.

Faculty

Joseph D. Khoury, MD

Professor
Department of Hematology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Joseph D. Khoury, MD, has no real or apparent conflicts of interest to report.
Aaron C. Logan, MD, PhD

Associate Professor
Division of Hematology and Blood and Marrow Transplantation
University of California, San Francisco
San Francisco, California

Aaron C. Logan, MD, PhD, has disclosed that he has received consulting fees from Amgen.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with acute lymphoblastic leukemia.

Goal

The goal of this activity is to improve participants’ knowledge and competence regarding the use of measurable residual disease in acute lymphoblastic leukemia and other hematologic malignancies.

Physician Continuing Medical Education

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.

Pharmacist Continuing Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-420-H01-P

Type of Activity: Application

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 01, 2018, through October 31, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable resource guide for patients who are receiving an FDA-approved BTK inhibitor, acalabrutinib or ibrutinib, from CCO.

Released: June 20, 2019

Downloadable slides on treatment strategies for CLL including the most recent data on BTK inhibitors, BCL-2 inhibitor, PI3K inhibitors, and CAR T-cell therapy.

John M. Burke, MD Nicole Lamanna, MD Released: June 19, 2019

Enter characteristics of your patient with acute myeloid leukemia (AML) into this online tool to receive treatment recommendations from 5 experts

Jeffrey E. Lancet, MD Farhad Ravandi, MD B Douglas Smith B. Douglas Smith, MD Roland B. Walter, MD, PhD, MS Eunice S. Wang, MD Released: June 12, 2019

Results from a phase II trial of ibrutinib, lenalidomide, and rituximab in non-GCB DLBCL as reported by CCO from ASCO 2019

Released: June 11, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?